Essiac

Essiac is an herbal preparation believed, in complementary and alternative medicine, to be a treatment for cancer. Its name derives from the backwards spelling of the surname of Rene M. Caisse, RN, a Canadian nurse (1888-1978) who was its greatest advocate. She said it was based on Native American healing, specifically from the Canadian Ojibways, and first described it in the 1920s. Caisse kept her exact ingredients and preparation secret, although it has been sold to a Canadian company that claims to provide the original formumation.

While formulas vary, the ingredients most often cited, some of which are reported to have possible immulomodulatory effects, are:

• Indian rhubarb (Rheum palmatum)
• Burdock root (Arctium lappa)
• Sheep sorrel (Rumex acetosella)
• Slippery elm (Ulmus fulva)

Some preparations include additional ingredients, such as:

• blessed thistle (Cnicus benedictus)
• red clover (Trifolium pratense)
• kelp (Laminaria digitata)
• watercress (Nasturtium officinale)
• cat's claw (Uncaria tomentosa)

Clinical experience

There is anecdotal evidence for efficacy, but Caisse was hostile to randomized controlled trials, admittedly of a period in which they were much less refined. In the 1970s, a study was done, but not published, at Sloan-Kettering Memorial Hospital; informal reports say some findings showed no activity and others showed significant activity. The National Institutes of Health describe it as having a "C" rating, with no substantial evidence of either efficacy or danger.

In vitro analysis

The first known formal analysis of its effects were done at the Canadian College of Naturopathic Medicine in 2007,

Essiac exhibited significant antioxidant activity in the ABTS assay. A 20-fold dilution of Essiac also exhibited significant immunomodulatory effects, specifically through stimulation of granulocyte phagocytosis, increases in CD8+ cell activation, and moderately inhibiting inflammatory pathways. Essiac exhibited significant cell-specific cytotoxicity towards ovarian epithelial carcinoma cells (A2780). Importantly, a 20-fold dilution of Essiac showed significant inhibition of several cytochrome CYP450 enzymes, most notably CYP1A2 (37%) and CYP2C19 (24%). Essiac demonstrated dose-dependent inhibition of clot fibrinolysis. CONCLUSION: In vitro analysis of Essiac indicates significant antioxidant and immunomodulatory properties, as well as neoplastic cell specific cytotoxicity consistent with the historical properties ascribed to this compound. Importantly, significant CYP450 and fibrinolysis inhibition were also observed.